Chinese biopharma stocks jump as U.S. plans to continue drug licensing deals
A young female worker in protective gear carefully carries a container filled with blister-packaged capsules, a crucial step…
FDA approves Gilead HIV pill Bixlenvo designed to simplify treatment
Gilead Bixlenvo drug Courtesy: Gilead The Food and Drug Administration approved a once-daily HIV pill from Gilead that…
Amid the chip bear market, healthcare is breaking out: Chart of the Day
Moderna (MRNA) stock doubled on Wednesday and stole the show. But healthcare had already been quietly breaking out…
CNBC Daily Open: Watching Iran’s economy; a losing game for bonds
Treasury Secretary Scott Bessent speaking to CNBC on May 14th, 2026 from Beijing, China. CNBC Hello, this is…
We’re increasing our Eli Lilly price target after another beat-and-raise quarter
Eli Lilly on Wednesday reported better-than-expected quarterly results and raised its full-year guidance as the company’s portfolio of…
Market for psychedelic drugs to treat mental health gets a buy signal
Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement…
J&J falls despite a beat-and-raise quarter. Why we’re raising our price target anyways
Johnson & Johnson shares fell Tuesday despite a mostly strong second-quarter earnings report and an increase to its…
Johnson & Johnson has a chance to show it’s more than just a rotation winner
Johnson & Johnson shares have showed signs of life ahead of earnings. For the stock to keep running,…
Hantavirus cases spark surge in pharma, biotech stocks — here’s why
ILLUSTRATION of hantavirus testing concept with laboratory tubes containing cotton swabs and HANTAVIRUS labels photographed in front of…
Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7B
Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company…
Goldman is betting Nvidia will get a boost from health care as industry builds out AI capabilities
Nvidia will get a boost as companies in the health care and life sciences industries increase their push…
Every Cure’s drug repurposing could change rare disease treatment
Dr. David Fajgenbaum, one of the founders of Every Cure, a nonprofit focused on drug repurposing. Courtesy of…